The TP53 tumor suppressor gene is directly regulated by BCL6, which represses its transcription in GCB DLBCLs [23] and its inactivation has been correlated with a poor prognosis in patients with DLBCL treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy or rituximab plus CHOP (R-CHOP) [24]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.